Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APYX NASDAQ:NTRB NASDAQ:OSRH NASDAQ:TELA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPYXApyx Medical$1.88-2.3%$2.13$0.76▼$2.73$70.35M1.43112,044 shs87,816 shsNTRBNutriband$6.43+4.1%$7.52$3.72▼$11.78$71.64M1.13136,819 shs106,155 shsOSRHOSR$0.62-13.9%$0.92$0.45▼$13.40$13.46M1.513.70 million shs1.03 million shsTELATELA Bio$1.64-5.7%$1.86$0.86▼$3.26$64.98M0.84171,865 shs131,807 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPYXApyx Medical-3.52%-7.69%+9.71%+15.66%+44.36%NTRBNutriband-4.64%-4.34%-16.51%-24.57%+51.23%OSRHOSR-6.74%-25.96%+12.75%-46.75%+72,419,900.00%TELATELA Bio-2.25%-3.33%-6.45%-7.45%-40.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPYXApyx Medical2.5109 of 5 stars0.04.00.04.23.31.70.6NTRBNutriband2.7367 of 5 stars3.53.00.00.02.31.70.6OSRHOSRN/AN/AN/AN/AN/AN/AN/AN/ATELATELA Bio2.3103 of 5 stars3.32.00.00.02.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPYXApyx Medical 2.67Moderate BuyN/AN/ANTRBNutriband 3.00Buy$13.00102.33% UpsideOSRHOSR 0.00N/AN/AN/ATELATELA Bio 2.50Moderate Buy$4.50174.39% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPYXApyx Medical$48.10M1.47N/AN/A$0.20 per share9.38NTRBNutriband$2.14M33.48N/AN/A$0.58 per share11.08OSRHOSRN/AN/AN/AN/A$6.45 per shareN/ATELATELA Bio$69.30M0.94N/AN/A$0.23 per share7.13Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPYXApyx Medical-$23.46M-$0.45N/AN/AN/A-37.11%-158.22%-28.30%11/7/2025 (Estimated)NTRBNutriband-$10.48M-$0.90N/AN/AN/A-415.93%-68.25%-60.40%N/AOSRHOSR-$2.41MN/A0.00∞N/AN/A-12.19%-8.18%N/ATELATELA Bio-$37.84M-$1.12N/AN/AN/A-54.12%-329.48%-57.34%11/6/2025 (Estimated)Latest OSRH, NTRB, TELA, and APYX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025OSRHOSRN/A$0.02N/A$0.02N/A$1.14 million8/11/2025Q2 2025TELATELA Bio-$0.18-$0.22-$0.04-$0.22$20.67 million$20.20 million8/7/2025Q2 2025APYXApyx Medical-$0.0933-$0.09+$0.0033-$0.09$11.69 million$11.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPYXApyx MedicalN/AN/AN/AN/AN/ANTRBNutribandN/AN/AN/AN/AN/AOSRHOSRN/AN/AN/AN/AN/ATELATELA BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPYXApyx Medical4.614.723.95NTRBNutriband0.013.713.48OSRHOSRN/A0.180.17TELATELA Bio4.143.192.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPYXApyx Medical55.33%NTRBNutriband19.70%OSRHOSR55.30%TELATELA Bio94.35%Insider OwnershipCompanyInsider OwnershipAPYXApyx Medical15.20%NTRBNutriband54.09%OSRHOSR33.67%TELATELA Bio4.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPYXApyx Medical27037.82 million32.07 millionOptionableNTRBNutriband1011.15 million5.12 millionNot OptionableOSRHOSRN/A21.58 million14.32 millionN/ATELATELA Bio12039.62 million37.75 millionOptionableOSRH, NTRB, TELA, and APYX HeadlinesRecent News About These Companies200,000 Shares in TELA Bio, Inc. $TELA Acquired by Paradigm Capital Management Inc. NYSeptember 2 at 8:34 AM | marketbeat.com747,410 Shares in TELA Bio, Inc. $TELA Acquired by Velan Capital Investment Management LPAugust 31 at 7:15 AM | marketbeat.comStonepine Capital Management LLC Has $2.51 Million Stake in TELA Bio, Inc. $TELAAugust 26, 2025 | marketbeat.comTELA Bio (NASDAQ:TELA) Shares Down 2.9% - Here's What HappenedAugust 23, 2025 | marketbeat.comAroa Biosurgery Reports Strong Growth and Expands Product Range Amid Market ChallengesAugust 20, 2025 | msn.comTela Bio reports Q2 EPS (22c), consensus (19c)August 13, 2025 | msn.comTELA Bio (NASDAQ:TELA) Issues Earnings ResultsAugust 12, 2025 | marketbeat.comTela Bio backs FY25 revenue view $85M-$88M, consensus $86.05MAugust 12, 2025 | msn.comTela Bio reiterates $85M–$88M 2025 revenue target as international expansion acceleratesAugust 12, 2025 | msn.comTELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue EstimatesAugust 11, 2025 | zacks.comTELA Bio, Inc. (TELA) Q2 2025 Earnings Call TranscriptAugust 11, 2025 | seekingalpha.comTELA Bio Reports Second Quarter 2025 Financial ResultsAugust 11, 2025 | globenewswire.comTELA Bio Inc (TELA) Q2 2025 Earnings Report Preview: What To ExpectAugust 10, 2025 | finance.yahoo.comTELA Bio Awards Inducement Equity Grants to New EmployeesAugust 10, 2025 | msn.comTELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 8, 2025 | globenewswire.comTELA Bio (TELA) Expected to Announce Quarterly Earnings on MondayAugust 5, 2025 | marketbeat.comTELA Bio to Participate in the Canaccord Genuity 45th Annual Growth ConferenceJuly 23, 2025 | globenewswire.comTELA Bio to Announce Second Quarter 2025 Financial ResultsJuly 21, 2025 | globenewswire.comTELA Bio, Inc. (TELA) Latest Stock News & Headlines - Yahoo FinanceJuly 19, 2025 | finance.yahoo.comBreakeven On The Horizon For TELA Bio, Inc. (NASDAQ:TELA)July 3, 2025 | finance.yahoo.comTELA Bio Welcomes Jim Hagen with Strategic Equity GrantJune 9, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOSRH, NTRB, TELA, and APYX Company DescriptionsApyx Medical NASDAQ:APYX$1.88 -0.05 (-2.34%) As of 03:20 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. The company's Helium Plasma Technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures various hand pieces for open and laparoscopic procedures; and OEM generators, as well as related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.Nutriband NASDAQ:NTRB$6.42 +0.26 (+4.13%) As of 03:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.OSR NASDAQ:OSRH$0.62 -0.10 (-13.88%) As of 03:08 PM EasternOSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D "platform technologies" versus "assets only" companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.TELA Bio NASDAQ:TELA$1.64 -0.10 (-5.75%) As of 03:24 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Loop Industries Insiders Buy Stock, Signal Confidence in Outlook Joby Aviation's Pullback: A Gift for Investors Who See the Future Opera Limited Stock Set to End 2025 on a High Note Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
